Transcriptional Comparison of Human and Murine Retinal Neovascularization

Laurenz Pauleikhoff1,2, Stefaniya Boneva1, Myriam Boeck1,3

  • 1Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Abstract

Insights

The oxygen-induced retinopathy (OIR) mouse model partially mimics human proliferative diabetic retinopathy (PDR) by activating similar biological pathways, despite limited gene overlap. This suggests conserved targets for PDR treatment.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Genomics

Background:

  • Retinal neovascularization (RNV) causes vision loss in proliferative diabetic retinopathy (PDR).
  • Current PDR treatments have high failure rates, necessitating new therapeutic targets.
  • Existing diabetic retinopathy animal models do not develop RNV, limiting research.

Purpose of the Study:

  • To compare gene expression profiles between the oxygen-induced retinopathy (OIR) mouse model and human PDR RNV membranes.
  • To assess the molecular similarity and identify conserved factors between the OIR model and human PDR.
  • To evaluate the OIR model's suitability for studying human PDR.

Main Methods:

  • RNA sequencing was performed on murine OIR retinas and human PDR RNV membranes.
  • Differential gene expression (DEG) analysis was conducted comparing RNV tissue to controls.
  • Biological processes and phylogenetically conserved factors were identified and compared between species.

Main Results:

  • 213 murine and 1223 human specific upregulated factors were identified.
  • A small overlap of 94 DEG (7% of human DEG) was observed between species.
  • Similar biological processes, including angiogenesis and immune response regulation, were activated in both OIR and PDR.

Conclusions:

  • Despite limited individual gene overlap, the OIR model activates conserved biological pathways relevant to human PDR.
  • The OIR model has both potential and limitations for studying human PDR.
  • Conserved factors like ANGPT2, S100A8, MCAM, EDNRA, and CCR7 represent potential therapeutic targets for PDR.

Related Concept Videos